{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:21:00Z","timestamp":1790191260778,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.10.065","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T16:58:42Z","timestamp":1667667522000},"page":"7187-7190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50\u201364 years in the United States"],"prefix":"10.1016","volume":"40","author":[{"given":"Jessica","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Sharkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.065_b0005","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4."},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.065_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.065_b0015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2022.10.065_b0020","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1016\/j.vaccine.2021.04.053","article-title":"An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study","volume":"39","author":"McGirr","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.10.065_b0025","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2021.1879579","article-title":"to September 2019","volume":"17","author":"Patterson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.065_b0030","unstructured":"Jatlaoui TC, Hung MC, Srivastav A, et al. Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2019\u20132020. Accessed 13 Sep 2022. Available at: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2019-2020.html."},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.065_b0035","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.065_b0040","unstructured":"Umansky D. Shingles Vaccine Shortage: What You Must Know. Consumer Reports. 05 March 2019. Accessed 3 Nov 2021. Available at: https:\/\/www.consumerreports.org\/shingles-vaccine\/shingles-vaccine-shortage-shingrix-availability\/."},{"key":"10.1016\/j.vaccine.2022.10.065_b0045","doi-asserted-by":"crossref","unstructured":"Schmader KE, Levin MJ, Grupping K, et al. The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. J Gerontol A Biol Sci Med Sci 2019; 74:1217-24.","DOI":"10.1093\/gerona\/gly218"},{"issue":"36","key":"10.1016\/j.vaccine.2022.10.065_b0050","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1016\/j.vaccine.2021.07.050","article-title":"Insurance reimbursements for recombinant zoster vaccine in the private sector","volume":"39","author":"Leidner","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.065_b0055","unstructured":"Liow C, Gillen EM, Becker L, Trost A, Young J. Updated Analysis Finds Sustained Drop in Routine Vaccines Through 2020. June 9, 2021. Accessed 26 Aug 2021. Available at: https:\/\/avalere.com\/insights\/updated-analysis-finds-sustained-drop-in-routine-vaccines-through-2020."},{"issue":"4","key":"10.1016\/j.vaccine.2022.10.065_b0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.amepre.2021.03.023","article-title":"Racial\/Ethnic and Socioeconomic Disparities in Adult Vaccination Coverage","volume":"61","author":"Kawai","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.065_b0065","first-page":"CD003941","article-title":"Patient reminder and recall interventions to improve immunization rates","volume":"1","author":"Jacobson Vann","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:22:07Z","timestamp":1759404127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":13,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22013287"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50\u201364 years in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}